Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
X
LinkedIn
Instagram
Search
×
HOME
PSYCH. BULLETIN
LATEST ISSUE
BLACK BOOK OF DOSING & MONITORING
RATING SCALES
LICENSING INFORMATION
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOPHARMACOLOGY 101
NEWS
Charles B. Nemeroff, MD, PhD: Duloxetine for the Treatment of Major Depressive Disorder
1
x
$
30.00
Escitalopram: A Second-Generation SSRI
1
x
$
0.00
Sophie Robert, PharmD - An Open-Label Assessment of Aripiprazole in the Treatment of PTSD
1
x
$
30.00
Roland Kuhn-100th Birthday of an Innovator of Clinical Psychopharmacology
1
x
$
30.00
New Developments in Depression and Anxiety Disorders
1
x
$
30.00
A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide
1
x
$
30.00
View Cart
Checkout
Home
intranasal
“A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide” has been added to your cart.
View cart
Sort by
Date
Sort by
Name
Sort by
Price
Sort by
Date
Sort by
Popularity
Show
20 Products
Show
20 Products
Show
40 Products
Show
60 Products
A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide
$
30.00
Add to cart
Details
Page load link
Go to Top